
FDA Approves Corcept’s Lifyorli™ Combo for Platinum-Resistant Ovarian Cancer
U.S. Food and Drug Administration Approves Corcept’s Lifyorli™ (relacorilant) Combination Therapy for Platinum-Resistant Ovarian Cancer Corcept Therapeutics Incorporated has announced a major regulatory milestone with the approval of its novel therapy, Lifyorli™ (relacorilant), by the U.S. Food and Drug Administration.…












